It's unclear why the study co-funded by Hotez — published in 2017 — wasn't covered under a pause that NIH had implemented on gain-of-function research at the time
Perhaps most baffling:
While Hotez has described the possibility of a lab origin of SARS-CoV-2 as "outlandish," his grant was premised in part on preparing for a possible lab release of SARS-CoV
On a personal note I'm happy to return to my roots: Live tweeting a niche advisory committee meeting
University of Maryland virologist Matthew Frieman argues that any further restrictions could prevent comparing vaccine efficacy against variants in the lab